Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023115 | 1.00 | TACR1 (0.53) | TACR1PPARAKLK7ACEKLK5 | |
| SCHEMBL5159314 | 0.95 | CTSS (0.49) | TACR1ACEKLK5CTSSCTSL | |
| SCHEMBL1023004 | 0.92 | ACE (0.54) | PPARAACECTSSCTSLCTSB | |
| SCHEMBL1023002 | 0.92 | ACE (0.54) | PPARAACECTSSCTSLCTSB | |
| SCHEMBL14497709 | 0.91 | CTSS (0.45) | TACR1ACECTSSCTSLCTSB | |
| SCHEMBL14497789 | 0.90 | REN (0.51) | TACR1CTSSCTSLCTSKPOLB | |
| SCHEMBL14497790 | 0.89 | CTSB (0.47) | TACR1ACEKLK5CTSSCTSL | |
| SCHEMBL14497707 | 0.89 | CTSS (0.49) | KLK7KLK5CTSSCTSLCTSB | |
| SCHEMBL14497792 | 0.87 | MME (0.47) | TACR1ACECTSSCTSLCTSB | |
| SCHEMBL14497708 | 0.87 | MEN1 (0.44) | TACR1PPARAKLK7ACEKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
| US-20070129288-A1 | Antibacterial amide macrocycles | BAYER HEALTHCARE AG (DE) | 2007-06-07 | — | — | US | disclosed |
| US-20060258571-A1 | Antibacterial ester macrocycles | AICURIS GMBH & CO. KG (DE) | 2006-11-16 | — | — | US | disclosed |
| US-20050256037-A1 | Antibacterial amide macrocyles | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | US | disclosed |
| EP-1515983-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106480-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129288-A1 | Antibacterial amide macrocycles | AADAC, AAAS, MRPL21 | TACR1 2316/4885PPARA 343/4885KLK7 3573/4885 |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | TACR1 2730/4885PPARA 169/4885KLK7 3789/4885 |
| US-20050256037-A1 | Antibacterial amide macrocyles | AADAC, PAM, NOD2 | TACR1 2610/4885PPARA 80/4885KLK7 3806/4885 |
| US-20060258571-A1 | Antibacterial ester macrocycles | TECR, MRPL21, CYP51A1 | TACR1 2875/4885PPARA 149/4885KLK7 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.